Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Revakinagene taroretcel is an encapsulated cell therapy that delivers therapeutic doses of ciliary neurotropic factor (CNTF) -- 200,000-440,000 allogeneic retinal pigment epithelial cells ...

Note the small amount of adjacent vitreous hemorrhage ... The superior half of the photograph shows bare retinal pigment epithelium. This patient underwent pars plana vitrectomy, which also ...

While there were whitish streaks of cortical opacity in the cataract, the nucleus was brunescent and dark in color, hinting at ... anterior chamber to check for vitreous. While no vitreous ...

Encelto is supplied as a single-dose implant containing 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human CNTF. It is implanted intravitreally during a ...

Beneath them lies a layer of crucial support tissue, known as retinal pigment epithelium (RPE ... director at medical practice Retina Vitreous Associates of Florida in St Petersburg.

Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.

The average area of retinitis was 66.2 mm 2. Localised posterior vitreous detachment was seen in 83% of eyes and posterior hyaloid precipitates were noted in (n=7,39%) of eyes. Retinitis without ...